Clinical Trial Update: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a dose-adjusted FOLFIRINOX regimen in elderly patients with metastatic pancreatic cancer reports efficacy and tolerability results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Pancreatic Metastatic Cancer, Toxicity | Phase 2 | Status: COMPLETED | Results posted: 2026-04-15